Pemvidutide
Also known as: ALT-801, ALT801
Classification
Peptide
Regulatory Status
n/a
Sources
3
Review
n/a
Overview
Pemvidutide (ALT-801) is an investigational unacylated peptide dual agonist of the GLP-1 and glucagon receptors, studied for MASLD/MASH and obesity.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
incretin-signalingenergy-expenditurehepatic-lipid-metabolismGLP-1 receptor agonismglucagon receptor agonismGLP-1RGCGR
Interactions & cautions
Drug interactions
other GLP-1, dual, or triple incretin agonists — Additive GI effects, glycemic effects, or monitoring burden may occur. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw